Systematic antigenic profiling of hematopoietic antigens on ovarian carcinoma cells identifies membrane proteins for targeted therapy development

American Journal of Obstetrics and Gynecology

Volumn 201, Issue 2, 2009, Pages 196.e1-196.e7

  Helpman, Limor ^a,d   Katz, Ben Zion ^a,d   Safra, Tamar ^a,d   Schreiber, Letizia ^b,d   Levine, Zurit ^c   Nemzer, Sergey ^c   Kinar, Yaron ^c   Grisaru, Dan ^a,d  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b WOLFSON MEDICAL CENTER   (Israel)

^c Compugen Ltd ^*  (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

bioinformatics; flow cytometry; hematopoietic antigens; ovarian cancer

Indexed keywords

ANTIGEN; CD15 ANTIGEN; CD71 ANTIGEN; ESTROGEN; MEMBRANE PROTEIN; SYNDECAN 1;

ANTIGEN EXPRESSION; ARTICLE; BIOINFORMATICS; CANCER CELL CULTURE; CARCINOMA CELL; CELL SUBPOPULATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEMBRANE MARKER; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; STAINING; VALIDATION STUDY;

EID: 67651124930     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2009.05.013     Document Type: Article

References (32)

1. Bhoola S., and Hoskins W.J. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol 107 (2006) 1399-1410
2. Giles F., Estey E., and O'Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer 98 (2003) 2095-2104
3. Sehn L.H., and Connors J.M. Treatment of aggressive non-Hodgkin's lymphoma: a North American perspective. Oncology (Williston Park) 19 (2005) 26-34
4. Chambers S.A., and Isenberg D. Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus 14 (2005) 210-214
5. Deininger M., Buchdunger E., and Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105 (2005) 2640-2653
6. Ohno R. Treatment of chronic myeloid leukemia with imatinib mesylate. Int J Clin Oncol 11 (2006) 176-183
7. Kane R.C., Bross P.F., Farrell A.T., and Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8 (2003) 508-513
8. Cavo M. Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia 20 (2006) 1341-1352
9. Finn R.S., and Slamon D.J. Monoclonal antibody therapy for breast cancer: herceptin. Cancer Chemother Biol Response Modif 21 (2003) 223-233
10. Kubota T. Gastrointestinal stromal tumor (GIST) and imatinib. Int J Clin Oncol 11 (2006) 184-189
11. de Silva C.M., and Reid R. Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathol Oncol Res 9 (2003) 13-19
12. Wagner U., Kohler S., Reinartz S., et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin Cancer Res 7 (2001) 1154-1162
13. Nicholson S., Bomphray C.C., Thomas H., et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunol Immunother 53 (2004) 809-816
14. Delord J.P., Allal C., Canal M., et al. Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma. Ann Oncol 16 (2005) 1889-1897
15. Tai C.J., Lo H.Y., Hsu C.H., Tai C.J., and Liu W.M. Remission of a negative Her2/Neu overexpressive metastatic ovarian cancer patient by the single agent of trastuzumab as salvage therapy. Gynecol Oncol 101 (2006) 184-185
16. Annab L.A., Hawkins R.E., Solomon G., Barrett J.C., and Afshari C.A. Increased cell survival by inhibition of BRCA1 using an antisense approach in an estrogen responsive ovarian carcinoma cell line. Breast Cancer Res 2 (2000) 139-148
17. Grisaru D., Hauspy J., Prasad M., et al. Microarray expression identification of differentially expressed genes in serous epithelial ovarian cancer compared with bulk normal ovarian tissue and ovarian surface scrapings. Oncol Rep 18 (2007) 1347-1356
18. Davidson B., Berner A., Nesland J.M., et al. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions. Hum Pathol 31 (2000) 1081-1087
19. Davidson B., Gotlieb W.H., Ben-Baruch G., et al. Expression of carbohydrate antigens in advanced-stage ovarian carcinomas and their metastases-A clinicopathologic study. Gynecol Oncol 77 (2000) 35-43
20. Shi W., Hemminki A., and Bartlett J.S. Capsid modifications overcome low heterogeneous expression of heparan sulfate proteoglycan that limits AAV2-mediated gene transfer and therapeutic efficacy in human ovarian carcinoma. Gynecol Oncol 103 (2006) 1054-1062
21. Ahmed N., Riley C., Rice G., and Quinn M. Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin Exp Metastasis 22 (2005) 391-402
22. Monniaux D., Huet-Calderwood C., Le Bellego F., Fabre S., Monget P., and Calderwood D.A. Integrins in the ovary. Semin Reprod Med 24 (2006) 251-261
23. Dijkgraaf I., Kruijtzer J.A., Frielink C., et al. Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide. Int J Cancer 120 (2007) 605-610
24. Londrigan S.L., Sutherland R.M., Brady J.L., et al. Prolonged local expression of anti-CD4 antibody by adenovirally transduced allografts can promote long-term graft survival. J Gene Med 8 (2006) 42-52
25. Hagberg H., Pettersson M., Bjerner T., and Enblad G. Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4). Med Oncol 22 (2005) 191-194
26. Shmelkov S.V., St Clair R., Lyden D., and Rafii S. AC133/CD133/Prominin-1. Int J Biochem Cell Biol 37 (2005) 715-719
27. Singh S.K., Clarke I.D., Hide T., and Dirks P.B. Cancer stem cells in nervous system tumors. Oncogene 23 (2004) 7267-7273
28. Oppliger Leibundgut E., Horn M.P., Brunold C., et al. Hematopoietic and endothelial progenitor cell trafficking in patients with myeloproliferative diseases. Haematologica 91 (2006) 1465-1472
29. Ferrandina G., Bonanno G., Pierelli L., et al. Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer 18 (2008) 506-514
30. Sever M., Jones T.D., Roth L.M., et al. Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary: diagnostic and therapeutic implications. Mod Pathol 18 (2005) 1411-1416
31. Brustmann H. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study. Gynecol Oncol 98 (2005) 396-402
32. Coleman R.L., Broaddus R.R., Bodurka D.C., et al. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 101 (2006) 126-131